Oct 15, 2026 08:30AM
Oct 8, 2026 08:56AM
Oct 1, 2026 08:26AM
Sep 16, 2026 09:17AM
Sep 10, 2026 08:21AM
Sep 10, 2026 08:00AM
Aug 24, 2026 08:01AM FDA grants fast track status to Erasca's ERAS-0015 for pancreatic cancer
Aug 24, 2026 08:00AM
Aug 11, 2026 04:01PM
Aug 10, 2026 08:02AM
Aug 10, 2026 08:00AM
Jul 13, 2026 04:01PM
Jul 13, 2026 04:01PM
Feb 17, 2026 10:48AM Registration Momentum Builds Across the Oncology Pipeline
Jan 12, 2026 08:03AM
Nov 19, 2025 09:45AM
Aug 12, 2025 04:01PM
Jun 2, 2025 08:06AM
Jun 2, 2025 08:00AM
May 13, 2025 04:05PM
May 13, 2025 08:04AM Erasca, Inc (ERAS) Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
May 13, 2025 08:00AM
Mar 25, 2025 04:31PM
Mar 20, 2025 04:01PM
Nov 12, 2024 04:01PM
Oct 24, 2024 08:02AM
Oct 24, 2024 08:00AM
Sep 25, 2024 08:00AM Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Aug 12, 2024 04:01PM
Jun 18, 2024 08:00AM
May 16, 2024 08:03PM
May 16, 2024 08:02PM
May 8, 2024 04:01PM
Apr 24, 2024 04:05PM
Mar 27, 2024 04:01PM Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM
Dec 11, 2023 08:03AM
Dec 11, 2023 08:00AM
Nov 28, 2023 08:00AM
Aug 10, 2023 04:01PM
Jun 22, 2023 04:01PM Erasca, Inc (ERAS) Granted FDA Orphan Drug Designation for ERAS-801
Jun 22, 2023 04:01PM
May 25, 2023 05:00PM
May 15, 2023 04:01PM
May 1, 2023 08:03AM
May 1, 2023 08:00AM
Apr 10, 2023 08:04AM
Apr 10, 2023 08:00AM Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
Mar 23, 2023 04:01PM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All